Shares of Cancer Genetics Inc (NASDAQ:CGIX) have earned an average recommendation of “Hold” from the six brokerages that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $6.00.

Several analysts have recently weighed in on CGIX shares. Maxim Group set a $6.00 price objective on Cancer Genetics and gave the stock a “buy” rating in a report on Wednesday, December 13th. HC Wainwright set a $6.00 price objective on Cancer Genetics and gave the stock a “buy” rating in a report on Wednesday, November 29th. Zacks Investment Research lowered Cancer Genetics from a “hold” rating to a “sell” rating in a report on Wednesday, October 4th. Finally, ValuEngine lowered Cancer Genetics from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st.

Shares of Cancer Genetics (NASDAQ CGIX) opened at $1.85 on Monday. Cancer Genetics has a fifty-two week low of $1.30 and a fifty-two week high of $5.30. The firm has a market capitalization of $51.25, a P/E ratio of -1.91 and a beta of 1.11. The company has a current ratio of 2.01, a quick ratio of 2.01 and a debt-to-equity ratio of 0.18.

In other news, Director John Pappajohn acquired 150,000 shares of the firm’s stock in a transaction dated Friday, December 8th. The shares were bought at an average price of $1.86 per share, with a total value of $279,000.00. Following the acquisition, the director now owns 2,781,204 shares of the company’s stock, valued at $5,173,039.44. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 21.30% of the stock is currently owned by company insiders.

A number of hedge funds have recently made changes to their positions in CGIX. Northern Trust Corp boosted its stake in Cancer Genetics by 61.0% in the 2nd quarter. Northern Trust Corp now owns 32,122 shares of the medical research company’s stock valued at $127,000 after buying an additional 12,168 shares in the last quarter. Thompson Davis & CO. Inc. boosted its stake in Cancer Genetics by 5,465.0% in the 2nd quarter. Thompson Davis & CO. Inc. now owns 111,300 shares of the medical research company’s stock valued at $440,000 after buying an additional 109,300 shares in the last quarter. Granahan Investment Management Inc. MA boosted its stake in Cancer Genetics by 26.3% in the 3rd quarter. Granahan Investment Management Inc. MA now owns 237,431 shares of the medical research company’s stock valued at $641,000 after buying an additional 49,371 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in Cancer Genetics by 61.9% in the 2nd quarter. Vanguard Group Inc. now owns 516,785 shares of the medical research company’s stock valued at $2,041,000 after buying an additional 197,619 shares in the last quarter. 11.13% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This story was first published by Watch List News and is owned by of Watch List News. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://www.watchlistnews.com/cancer-genetics-inc-cgix-receives-consensus-rating-of-hold-from-analysts/1790693.html.

About Cancer Genetics

Cancer Genetics, Inc is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information.

Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.